drugset / Trial / NCT04615923

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923

Phase 2/3 Completed 163 enrolled Merit E. Cudkowicz, MD Prilenia · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.

Timeline

Start
2020-12-18
Primary completion
2022-07-14
Completion
2022-07-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pridopidine Small molecule 45 mg Oral